Edition:
Deutschland

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,358JPY
07:23 Uhr
Change (% chg)

¥45 (+3.43%)
Prev Close
¥1,313
Open
¥1,315
Day's High
¥1,372
Day's Low
¥1,315
Volume
555,900
Avg. Vol
993,844
52-wk High
¥2,219
52-wk Low
¥1,166

Select another date:

Wed, Jul 1 2020

BRIEF-Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger Of Tolero And Boston Biomedical

* SUMITOMO DAINIPPON PHARMA ONCOLOGY ANNOUNCES ITS FORMATION THROUGH MERGER OF TOLERO AND BOSTON BIOMEDICAL Source text for Eikon: Further company coverage:

BRIEF-Myovant Sciences Announces FDA Acceptance Of New Drug Application For Prostate Cancer Treatment

* MYOVANT SCIENCES ANNOUNCES PRIORITY REVIEW AND FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR ONCE-DAILY, ORAL RELUGOLIX FOR ADVANCED PROSTATE CANCER

BRIEF-U.S. FDA Approves Kynmobi For Treatment Of "Off" Episodes In Patients With Parkinson's Disease To Sunovion

* U.S. FDA APPROVES KYNMOBI FOR ACUTE, INTERMITTENT TREATMENT OF “OFF” EPISODES IN PATIENTS WITH PARKINSON’S DISEASE TO SUNOVION PHARMACEUTICALS Source text: (https://bit.ly/2LNrbwl) Further company coverage:

UPDATE 1-U.S. FDA approves Parkinson's treatment from Sunovion Pharma

May 21 The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon Pharma, for the treatment of "off" episodes in patients with Parkinson's disease, the company said.

BRIEF-Aquestive Says Expect To Receive Between Up To $100 Million Of Non-Dilutive Capital From Monetization Of Royalty Stream

* AQUESTIVE THERAPEUTICS ADVANCES ROYALTY MONETIZATION PLAN AS SUNOVION PHARMACEUTICALS’ APOMORPHINE SUBLINGUAL FILM THERAPY RECEIVES FDA APPROVAL

U.S. FDA approves Parkinson's treatment from Sunovion Pharma

May 21 The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon , for the treatment of "off" episodes in patients with Parkinson's disease, according to a label published by the agency.

BRIEF-Roivant Provides Updates For Pivotal Breathe Clinical Trial Evaluating Gimsilumab In COVID-19 Patients

* ROIVANT PROVIDES UPDATES FOR PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

BRIEF-Sumitovant Biopharma Reports Key Clinical And Regulatory Milestones By Myovant Sciences

* SUMITOVANT BIOPHARMA - REPORTS KEY CLINICAL AND REGULATORY MILESTONES BY MYOVANT SCIENCES

BRIEF-Poxel End-March Cash And Cash Equivalents Down At 36.9 Million Euros

* POXEL ANNOUNCES FIRST QUARTER 2020 FINANCIAL AND CORPORATE UPDATE

BRIEF-Roivant Doses First Patient In Trial Evaluating Gimsilumab In Covid-19 Patients For Treatment Of ARDS

* ROIVANT DOSES FIRST PATIENT IN PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19 PATIENTS FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME

Select another date: